How to buy Hikma Pharmaceuticals shares

Hikma Pharmaceuticals PLC (HIK) is a publicly traded drug manufacturers-specialty and generic business based in the UK. It opened the day at 2238p after a previous close of 2241p. During the day the price has varied from a low of 2202p to a high of 2243p. The latest price was 2213p (25 minute delay). Hikma Pharmaceuticals is listed on the London Stock Exchange (LSE) and employs 8,800 staff. All prices are listed in pence sterling.

Our top picks for where to buy Hikma Pharmaceuticals shares:

Best for

0% commission

PROMOTED FOR

US shares

Best for

Beginner investments

Best for

Beginners

Fees for buying 20x Hikma Pharmaceuticals shares with popular platforms

Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform	Customer rating	Platform fee	Min. initial deposit	Trading fee estimate
	★★★★★	£0	£1	£0.00 £442.60 total	Go to site Capital at risk
	★★★★★	£0	$50	£0.00 £442.60 total	Go to site Capital at risk
	★★★★★	£0	£250	£8.00 £450.60 total	Go to site Capital at risk
	Not yet rated	£0	No minimum	£0.00 £442.60 total	Go to site Capital at risk
	★★★★★	£0	No minimum	£0.00 £442.60 total	Go to site Capital at risk
	★★★★★	£0	£1	£11.95 £454.55 total	Go to site Capital at risk
	★★★★★	£0	£0.01	£1.81 £444.41 total	Go to site Capital at risk

Full comparison of share dealing platforms

Alternative ways to invest in Hikma Pharmaceuticals

• Invest in Hikma Pharmaceuticals via a fund

  Buying shares in just one company can leave you more exposed to unexpected swings in the market than if you have a range of investments - a "diversified portfolio". Experts generally recommend having a broad mix of assets and funds that hold a ready-made portfolio of at least 50 different companies' shares, on the basis that drops in the value of some will be offset by rises elsewhere.

  Hikma Pharmaceuticals is a major part of the LSE index, so it's included in many global funds and investment trusts, as well as tracker-style exchange traded funds (ETFs).

• Invest in Hikma Pharmaceuticals via FTSE 100

  Icon	Fund	5-year performance	1-year performance (to November 2022)	Link to invest
  	Vanguard FTSE 100 (VUKE)	16.32%	2.67%	Invest with FreetradeCapital at risk
  	iShares Core FTSE 100 (CUKX)	16.27%	2.45%	Invest with eToroCapital at risk
  	Invesco FTSE 100 (S100)	14.75%	2.06%	Invest with IGCapital at risk
  	HSBC FTSE 100 (HUKX)	16.09%	2.33%	Invest with IGCapital at risk
  	Lyxor FTSE 100 (100D)	15.09%	2.02%	Invest with IGCapital at risk
  	Xtrackers FTSE 100 (XDUK)	15.34%	1.81%	Invest with IGCapital at risk

Is it a good time to buy Hikma Pharmaceuticals stock?

Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.

Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.

• See the technical analysis gauge

• See Hikma Pharmaceuticals share price (LSE:HIK)

  Use our graph to track the performance of HIK stocks over time.

  Share price volatility

  Over the last 12 months, Hikma Pharmaceuticals's shares have ranged in value from as little as 1174.5p up to 2109.7589p. A popular way to gauge a stock's volatility is its "beta".

  Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Hikma Pharmaceuticals's is 0.3126. This would suggest that Hikma Pharmaceuticals's shares are less volatile than average (for this exchange).

• What's Hikma Pharmaceuticals price performance over time?

  Historical closes compared with the last close of 2213p

  1 week (2023-03-13)	28.36%
  1 month (2023-02-20)	25.13%
  3 months (2022-12-20)	44.88%
  6 months (2022-09-20)	79.77%
  1 year (2022-03-18)	7.43%
  2 years (2021-03-19)	0.05%
  3 years (2020-03-20)	17.46%
  5 years (2018-03-20)	98.92%

Invest in Hikma Pharmaceuticals shares

• Start investing from $50
• Pay no stamp duty on UK shares
• Commission-free trading. Other fees may apply.

Go to site

Capital at risk

Is Hikma Pharmaceuticals under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Hikma Pharmaceuticals P/E ratio, PEG ratio and EBITDA

• P/E ratio
• Hikma Pharmaceuticals PEG ratio
• Hikma Pharmaceuticals EBITDA

What's Hikma Pharmaceuticals's ESG track record?

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Hikma Pharmaceuticals.

Overall Hikma Pharmaceuticals ESG score

Hikma Pharmaceuticals's total ESG risk: 30.38

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Hikma Pharmaceuticals's overall score of 30.38 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Hikma Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

• Environmental
• Social
• Governance
• Controversy

Frequently asked questions

• Does Hikma Pharmaceuticals pay dividends?

  • Dividend yield
  • Forward yield
  • Payout ratio

  Dividend yield: 2.67% of stock value

  Forward annual dividend yield: 2.67% of stock value

  Dividend payout ratio: 63.16% of net profits

  Hikma Pharmaceuticals has recently paid out dividends equivalent to 2.67% of its share value annually.

  Hikma Pharmaceuticals has paid out, on average, around 63.16% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.67% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 2.67% return on their shares, in the form of dividend payments. In Hikma Pharmaceuticals's case, that would currently equate to about 56p per share.

  Hikma Pharmaceuticals's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

  The latest dividend was paid out to all shareholders who bought their shares by 23 March 2023 (the "ex-dividend date").

  • Hikma Pharmaceuticals dividend history

    Dividend	Type	Ex-dividend date	Payment date
    $0.18	Interim	19/08/2021	20/09/2021
    $0.34	Final	18/03/2021	26/04/2021
    $0.16	Interim	20/08/2020	21/09/2020
    $0.3	Final	19/03/2020	07/05/2020
    $0.14	Interim	22/08/2019	23/09/2019
    $0.26	Final	04/04/2019	22/05/2019
    $0.12	Interim	23/08/2018	21/09/2018
    $0.23	Final	05/04/2018	24/05/2018
    $0.11	Interim	24/08/2017	22/09/2017
    $0.22	Final	06/04/2017	25/05/2017
    $0.11	Interim	01/09/2016	30/09/2016
    $0.21	Final	07/04/2016	19/05/2016
    $0.11	Interim	27/08/2015	25/09/2015
    $0.04	Special	16/04/2015	21/05/2015
    $0.099	Final	16/04/2015	21/05/2015
    $0.07	Interim	27/08/2014	26/10/2014
    $0.04	Special	27/08/2014	26/10/2014
    $0.078	Final	23/04/2014	22/05/2014
    $0.024	Special	23/04/2014	22/05/2014
    $0.019	Special	04/09/2013	07/10/2013
    $0.045	Interim	04/09/2013	07/10/2013
    $0.1	Final	17/04/2013	23/05/2013
    $0.06	Interim	29/08/2012	08/10/2012
    $0.075	Final	18/04/2012	24/05/2012
    $0.055	Interim	07/09/2011	13/10/2011
    $0.075	Final	13/04/2011	26/05/2011
    $0.055	Interim	08/09/2010	14/10/2010
    $0.065	Final	14/04/2010	27/05/2010
    $0.04	Final	29/04/2009	02/06/2009
    $0.045	Interim	16/09/2009	16/10/2009
    $0.035	Interim	17/09/2008	17/10/2008
    $0.04	Final	30/04/2008	02/06/2008
    $0.035	Interim	26/09/2007	26/10/2007
    $0.021	Final	16/05/2007	18/06/2007
    $0.016	Interim	27/09/2006	27/10/2006
    $0.0047	Final	26/04/2006	30/05/2006

  Currently 29.629% of Hikma Pharmaceuticals shares are held by insiders and 40.131% by institutions.

• How many people work for Hikma Pharmaceuticals?

  Latest data suggests 8,800 work at Hikma Pharmaceuticals.

• When does the fiscal year end for Hikma Pharmaceuticals?

  Hikma Pharmaceuticals's fiscal year ends in December.

• Where is Hikma Pharmaceuticals based?

  Hikma Pharmaceuticals's address is: 1 New Burlington Place, London, United Kingdom, W1S 2HR

• What is Hikma Pharmaceuticals's ISIN number?

  Hikma Pharmaceuticals's international securities identification number is: GB00B0LCW083

• How to sell Hikma Pharmaceuticals shares

  It's as easy to sell Hikma Pharmaceuticals as it is to buy! Here's how to sell Hikma Pharmaceuticals that you already own.

  1. Open your investment app. If you've got one with desktop access, you can log in online
  2. Go to your portfolio. This should be in the main menu
  3. Find your shares. You may be able to search your portfolio
  4. Choose how many you'd like to sell. You'll be able to review the price and see how much you'll receive
  5. Sell your Hikma Pharmaceuticals shares. Your investment platform will let you know when your shares are sold

• Can you buy Hikma Pharmaceuticals shares with a debit card?

  Most share dealing providers in the UK will let you use your debit card to top up your account and buy shares. The main ways are with a debit card, bank transfer or with Apple/Google Pay.

• What's the easiest way to buy Hikma Pharmaceuticals shares?

  The easiest way to get hold of some Hikma Pharmaceuticals shares is to sign up for a share trading app and place a market order or basic order. This type of order tells the platform that you're interested, so it'll try to execute it as quickly as it can. It could take some time for the order to go through, especially if there's a lot of volatility in Hikma Pharmaceuticals shares.

• Do you need to complete a W8-BEN form if you want to invest in Hikma Pharmaceuticals

  If you're investing in a US stock, you'll need to complete a W8-BEN form to minimise your tax liability. Whether these are automatically handled for you depends on your broker, so it would be a good idea to check with them directly.

• What is the key financial information for Hikma Pharmaceuticals?

  Financials

  Revenue TTM	£2.5 billion
  Operating margin TTM	23.76%
  Gross profit TTM	£1.3 billion
  Return on assets TTM	8.45%
  Return on equity TTM	8.28%
  Profit margin	7.47%
  Book value	9.661p
  Market capitalisation	£3.8 billion

  TTM: trailing 12 months